MedTrace Logo

Chemotherapy Induction and Chemoradiotherapy in Patients With Esophageal Carcinoma

NCT00735345 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-03-09

No results posted yet for this study

Summary

The aim of this study is the evaluate the feasibility and safety of chemotherapy induction treatment combined with cetuximab followed by chemoradiotherapy combined with cetuximab in the treatment of patients with non-metastatic esophageal cancer.

Conditions

  • Esophageal Cancer

Interventions

DRUG

5-FU

750 mg/m2/d C.I. i.v.d1-5, d29-33 and 300 mg/m2/d C.I. i.v. on the days of radiotherapy

DRUG

Cisplatin

15 mg/m2/d i.v. d1-5, d29-33

DRUG

Taxotere

75 mg/m2/d i.v. d1 and d29, 15 mg/m2/d i.v. on d57, d64, d71 and d78

BIOLOGICAL

Cetuximab

Cetuximab: 400 mg/m2 i.v. d1; 250mg/m2 weekly d8 through d85

RADIATION

Radiation during chemoradio-immunotherapy

39.6 Gy total dose

Sponsors & Collaborators

Principal Investigators

  • Wolfgang Eisterer, Prof. Dr. · Medizinische Universitaet Innsbruck

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00735345 on ClinicalTrials.gov